Q4 2025 PAVmed Inc Earnings Call Transcript
Key Points
- PAVmed Inc (PAVM) successfully completed a restructuring recapitalization and financing, removing toxic convertible securities and achieving a clean capital structure.
- Lucid, a subsidiary of PAVmed Inc (PAVM), reported a 29% increase in EsoGuard test volume and a 24% increase in revenue from the previous quarter.
- Lucid secured a contract with the US Department of Veterans Affairs, expanding access to the nation's largest integrated healthcare system.
- Veris, another subsidiary, completed full Epic integration with Ohio State University, enhancing personalized cancer care through a digital health platform.
- PAVmed Inc (PAVM) is relaunching its MedTech portfolio with new leadership and a focus on innovative technologies, including a licensed endoscopic imaging technology from Duke University.
- PAVmed Inc (PAVM) experienced a GAAP net loss of $2.8 million in the fourth quarter, highlighting ongoing financial challenges.
- The company is focusing limited capital resources on getting Veris' implantable device to FDA submission, potentially delaying broader commercial expansion.
- Development of AI-based clinical decision support tools for Veris is still in early stages, requiring significant time and resources.
- The new imaging technology licensed from Duke University is still in early phases, with commercialization being a long-term goal.
- PAVmed Inc (PAVM) faces challenges in expanding its commercial team and resources to support broader market penetration for its subsidiaries.
Good morning, and welcome to the PAVmed's Fourth Quarter 2025 Business Update Conference Call. (Operator Instructions) This call is being recorded on Monday, March 30, 2026.
I would now like to turn the conference over to Matt Riley, PAVmed's Vice President of Investor Relations. Please go ahead.
Thank you, operator. Good morning, everyone. Thank you for participating in today's business update call. Joining me today on the call are Dr. Lishan Aklog, Chairman and CEO of PAVmed; along with Dennis McGrath, Chief Financial Officer.
The press release announcing our business update and financial results is available on PAVmed's website. Please take a moment to read the disclaimers about forward-looking statements in the press release. The business update press release and the conference call all include forward-looking statements, and these forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially from statements
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
